Purpose: We conducted a pilot study to assess the feasibility and the potential implications of detecting TERT promoter (TERTp)-mutant cell-free tumor-derived DNA (tDNA) in the cerebrospinal fluid (CSF) and plasma of glioblastoma patients.
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Statement of translational relevance
A clinical need exists to develop sensitive and specific biomarkers for glioblastoma diagnosis and recurrence detection. Recent studies have reported highly recurrent mutations in the TERT promoter region in > 90% of glioblastomas. These mutations have been further shown to be clonal and to confer a dismal prognosis. Consequently, if TERTp mutations could be detected in the CSF or plasma, this alteration could serve as a sensitive biomarker for glioblastomas. In this pilot study, we have established a clinical assay to detect TERTp mutations in the CSF-tDNA in patients with TERTp-mutant/IDH wild-type glioblastomas with 100% sensitivity and 92.1%
specificity. In addition, we show an independent association between the TERTp mutation variant allele fraction (VAF) in the CSF-tDNA and patients' survival. Although of exploratory nature, our results suggest that TERTp mutation detection in the CSF-tDNA has the potential to be a sensitive diagnostic tool in the management of glioblastoma patients.
Introduction:
Our knowledge about molecular markers in gliomas has undergone a rapid evolution in the last few years. Subsequently, a new generation of biomarkers has become available with the discovery of the genetic alterations that are responsible for the initiation and progression of gliomas, including telomerase reverse transcriptase promoter (TERTp) and isocitrate dehydrogenase (IDH) mutations (1) (2) (3) (4) (5) .
TERTp mutations are one of the most common recurrent alterations (90%) in glioblastomas and were found to be clonal in both pre-treatment and post-treatment autopsy samples in most glioblastoma patients (6) . Moreover, the presence of somatic TERTp mutations in glioblastomas confers a dismal prognosis (7, 8) . In contrast, only a minority of glioblastomas harbor IDH1 mutations (5%) and were shown to represent a distinct subset with favorable outcomes (5, 8) .
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Consequently, screening for TERTp and IDH1 mutations in glioblastoma patients is of clinical value in survival prediction.
The tDNA contains identical genetic alterations to those detected in the primary tumor itself.
Therefore, in numerous cancer types, circulating tDNA detection in the plasma has been shown to be a reliable tool for monitoring, diagnosis and prognostication (9) (10) (11) (12) (13) (14) (15) . However, in primary and metastatic brain tumors, the levels of tDNA in the plasma are low and inconsistently detectable (12). Moreover, tDNA assessment has not yet been established in the clinical management of glioma patients and, to date, no study has systematically evaluated the clinical value of TERTp mutation detection in the plasma or CSF in a large cohort of IDH wild-type glioblastomas.
With this in mind, we conducted a pilot prospective study to assess TERTp and IDH hotspot mutations in the CSF-tDNA and plasma-tDNA, collected during surgery. We exclusively evaluated data from patients with TERTp-mutant/IDH wild-type glioblastomas to reduce potential confounders. A further intention of our study is to explore a putative association between the burden of the TERTp mutation in the tDNA and patients' outcome.
Patients and Methods
Study population and intraoperative sample collection
Specimens were collected between July 2015 and September 2017 at the time of surgery from 60 patients who underwent tumor resection of newly diagnosed intracranial tumors that were suspicious for a diffuse glioma. Upon general anesthesia, 8-10 ml whole blood were withdrawn from every patient and 2-4 ml CSF were collected during surgery from the tumor site. The CSF collection was performed directly after opening the dura (durotomy), before any surgical 7 manipulation of the tumor, predominantly through dissection of the convexity subarachnoid space.
Blood and CSF samples were collected in specific tubes preserving the tDNA (cell free DNA-BCT Tubes, Streck, Omaha, NE, USA). For separation of plasma, blood samples were centrifuged at 300 g for 20 min. Without disturbing the buffy coat, the plasma layer (supernatant)
was carefully removed and transferred into a new 2 mL low-bind tube. We also collected the pelleted material to assess TERTp mutations in the cellular fraction of the CSF. To completely remove residual cells, both plasma and CSF samples were subsequently centrifuged at 5000 g for 10 min and stored at -20 °C until downstream processing.
The present study was conducted according to the guidelines of the Declaration of Helsinki and has been approved by the local Ethics Committee of the Medical Faculty Carl Gustav Carus
Dresden. All samples (CSF, blood and tumor tissue) were collected with written consent from the patients.
Tumor tissue preparation and DNA extraction
Tumor tissues were taken intraoperatively and were snap frozen at -80°C. Frozen tumor tissue was sectioned using a cryotome (Cryostat Jung CM 1800; Leica). To assure a tumor cell content of at least 80% for nucleic acid extraction, control slides stained with hematoxylin and eosin were examined by the local neuropathologist (M.M.). For DNA isolation, the QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) was used. 8 digestion buffer for 30 min at 55 °C in a water bath. After mixing with DNA binding buffer, samples were loaded into the Zymo-Spin III-S column assembly and centrifuged at 1.000 g for 2 min. After washing and centrifugation (10.000 g; 30 sec), ctDNA was eluted in 35 μL TE-buffer (10 mM Tris, 0.1 mM EDTA, pH8). The DNA concentration was measured by quantitative RealTime PCR on an ABI7500 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) using primers and probes for the ß-globin locus.
Extraction and quantification of cell-free DNA
PCR amplification of the TERT-promoter region
A nested PCR procedure was used to amplify the proximal TERT promoter covering nucleotide 
Library preparation, sequencing and data analysis
The PCR reactions were purified using a two-round purification process with Agencourt AMPure XP Reagent (Beckman Coulter, Krefeld, Germany) and eluted in 30-50 μl ddH 2 Figure S1 ). In addition, we determined the diagnostic sensitivity and specificity of our assay by analyzing DNA extracted from the CSF cellular components in patients with non-tumor-related hydrocephalus during shunt implantation (n=6). Digital droplet PCR (ddPCR) was performed on a Bio-Rad QX200 using the Bio-Rad TERT C228T_113 Assay (Assay ID dHsaEXD72405942). The detailed method is provided in the supporting information.
Digital PCR
IDH mutation detection in tumor tissue
IDH1/2 mutation detection was performed in the tumor tissue based on conventional Sanger sequencing, using established primer sets, as published elsewhere by our group (17) .
MGMT promoter methylation assessment in tumor tissue
MGMT promoter methylation status was determined by the methylation-specific polymerase chain reaction (MsPCR), as described by Esteller et al. (18) .
Radiological evaluation and volumetric measurements
All patients in the study received a pre-and postop. MRI (day one after surgery) with T1, T1 post-contrast, T2 and FLAIR sequences. Radiologic progression was determined using the criteria for Response Assessment in Neuro-Oncology (RANO) (19) . Additionally, the preoperative T1-weighted post-contrast MR scans were used to measure the enhancing tumor size and obtain volumetric measurements. A combination of manual segmentation using the ITK-SNAP software (20) and intensity filtering based on individually adjusted thresholds was used to select the enhancing tumor tissue with and without the necrotic tumor portion.
To investigate correlations between the successful detection of TERTp-mutant tDNA and tumor location, we used a previously described MRI-based classification of gliomas (21) 
Group 1
Tumor contacting SVZ and infiltrating cortex
Group 2
Tumor contacting SVZ but not involving cortex
Group 3
Tumor not contacting SVZ but involving cortex
Group 4
Tumor neither contacting SVZ nor infiltrating cortex
Statistical analysis
The Kaplan-Meier technique was used to estimate progression free survival (PFS) and overall
survival (OS) and tested for significance by the log-rank test. PFS was calculated from the day of surgery until MRI-confirmed tumor progression or end of follow-up. OS was defined as the interval from the day of first surgery until death or the end of follow-up. The Mann-Whitney U and Fisher's exact tests were used to test for association of clinical variables and CSF-tDNA, whereas the Spearman test was used to correlate coefficients among outcomes of the contrastenhancing tumor volume with the abundance of the mutant CSF-tDNA. Multivariate Cox regression models were applied to assess the impact of CSF-tDNA on patient's outcome. All p values are two-sided, and all analyses were conducted using the SPSS software package (Version 21.0 SPSS Inc., Chicago, IL, USA).
Results:
Patients' characteristics
Out of 60 patients who underwent surgery for an intracranial tumor, we identified 38 patients (24 males and 14 females) with TERTp-mutant/IDH wild-type glioblastomas who were enrolled into our study (Figure 1) . The median patient age at initial diagnosis was 67.6 years (range: 64.3 - 
years
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was applied in all cases, and 31 patients were treated concomitantly with temozolomide.
Temozolomide therapy was prematurely discontinued in seven patients, due to disease progression and in two patients because of hematologic toxicities.
Our study had a median follow-up of 12.36 months (4.25 -33.0 months). The median PFS of patients with a newly-diagnosed GBM was 5.7 months (4.2 -7.2 months) and the median OS was 9.9 months (6.7 -13.2 months). 29 patients (78.3%) passed away during the time of followup. The last update of progression status was performed in April 2018.
TERTp mutation detection
The median coverage for tumor tissue samples was 48170 reads (range 42716-60268 reads), for CSF it was 48890 reads (range 8680-198576 reads) and for plasma samples it was 49700 reads (range 6647-107900 reads). Using this approach, we could detect TERTp mutations in CSF-tDNA at allelic frequencies as low as 0.4% for C228T and 0.2% for C250T. The turnaround time from processing the CSF/plasma sample to final mutation data report was 3-5 days.
In the tumor tissue, the detected TERTp hotspot mutations were located at 146 bp (referred to as C250T, n=7) and in 31 cases at 124 bp (referred to as C228T) upstream of the translation start of the TERT promoter. In the matched CSF-tDNA, the TERTp mutation was successfully detected in 35 out of 38 patients (92.1%) ( Table 1) .
Remarkably, in four IDH-mutant/TERTp-mutant gliomas (oligodendrogliomas), we detected only one TERTp mutation in the CSF-tDNA (Supplementary Table 1 Table 1 ). Interestingly, the only patient with a tumor that was entirely encapsulated by the brain parenchyma (Group 4, Table 1 ) was one of the three patients with non-detectable TERTp mutations in the CSF (Supplementary Figure S2) .
Notably, we did not observe a significant association between the TERTp mutation VAF in the CSF-tDNA and patients' age, sex or performance status.
Association between TERTp mutation VAF in CSF-tDNA and patients' outcome
To explore a potential role of the TERTp mutation VAF in the CSF-tDNA in predicting patients' survival, Kaplan-Meier curves were generated and analyzed based on the TERTp mutation VAFs in the CSF-tDNA. It was concordantly observed, that patients with low VAF in the CSFtDNA had a longer OS when compared to patients with high VAF, irrespective of using the lower quartile VAF of 11.45%, the lower third VAF of 13% or the median VAF of 20.3% to dichotomize the patients (p = 0.035, p = 0.008 and p = 0.062, respectively) (Figure 4) .
To substantiate our findings, a multivariate analysis was performed including all first-diagnosed glioblastoma patients with detectable TERTp-mutant CSF-tDNA and available follow-up (n=29).
The TERTp mutation VAF with a cut off of 13% was found to be an independent prognostic factor for OS (p= 0.001, HR= 16.02, 95% CI: 3.15 -28.43) ( Table 2) . By exploring an interaction between the tumor volume and a TERTp mutation VAF cut off of 13% in the CSFtDNA as one factor in the multi-variate analysis, the HR was 2.07, 95% CI 1.33-3.22, p = 0.001.
All other included clinical parameters such as age, extent of resection, MGMT promoter status
were not independent prognostic factors in our cohort, although it is possible that there are other clinical variables which may account for the differences in outcome. 
Postoperative TERTp mutation detection in the CSF-tDNA
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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To examine a potential application of CSF-tDNA as a marker for postoperative residual disease, CSF was collected in five patients who had intraoperatively detectable TERTp mutation in the CSF-tDNA and underwent a lumbar drainage placement to treat a postoperative CSF leakage.
Interestingly, we saw a dramatic decrease of VAF levels (p= 0.043, Wilcoxon-signed rank test) (Supplementary Figure S3) . However, although GTR was achieved in all five patients, TERTp mutation in the CSF-tDNA was postoperatively detectable in only two cases. Remarkably, persistent postoperative TERTp mutation detection in the lumbar spine CSF was associated with a decreased PFS of both patients (5.1 months), compared with the three patients with nondetectable mutation who had a longer PFS (median 11.9 months, 95% CI 8.3 -15.5 months).
However, given the small group of patients, our study was likely underpowered to make any significant conclusions about differences in survival outcomes.
Discussion:
Detection of circulating tumor material has been shown to be of clinical value for diagnosis, prediction of response to treatment, and prognosis in cancer patients (10, 11, 14, 15, 22) . In this pilot study, we demonstrate that TERTp mutation detection in intraoperatively collected CSF is feasible with a very high sensitivity and specificity in glioblastoma with spatial relationship to a CSF reservoir in the brain, consistent with the findings from previous studies (23, 24) .
Remarkably, we observed a significant association between the VAF of the TERTp mutation in the CSF-tDNA and the outcome of glioblastoma patients in our cohort. Using different cutoffs, our data consistently showed that an increasing burden of TERTp-mutant alleles in the CSFtDNA was associated with unfavorable outcomes, suggesting a high reliability of the TERTp mutation VAF levels in the CSF-tDNA as an outcome prediction tool in glioblastoma patients. Furthermore, we found a lower sensitivity of TERTp mutation detection in a distinct subset of TERTp-mutant/IDH-mutant gliomas (oligodendrogliomas), confirming the findings of a recent study that reported on the inability to detect molecular alterations in the CSF-tDNA in some lowgrade gliomas (24) . This may be explained by the fact that glioblastomas have more severe blood-brain barrier integrity disruption compared to oligodendrogliomas, which is presumably associated with larger quantities of tDNA shedding into the CSF.
A further potential application for CSF-tDNA is its use as a marker for postoperative residual disease. Presently, predicting the disease-free status of patients is predominantly based on clinical and radiological criteria. Interestingly, fluctuations in circulating tDNA levels have been shown to occur prior to changes seen in imaging studies (10) . Moreover, it has been demonstrated that levels of circulating tDNA increase with disease progression and correspondingly decrease with response to therapy in solid tumors and glioblastomas (10, 11, 25, 26 ). In the current study, we demonstrate an association between patients' outcome and intra-/postoperative TERTp mutation CSF-tDNA levels in five cases. A significant postoperative reduction of the TERTp mutation VAF in the CSF-DNA when compared with the "baseline" intraoperative VAF level was associated with favorable survival outcomes. Although preliminary, this finding suggests that clearance of TERTp mutations in the CSF may indicate residual disease in glioblastoma patients and may be used for disease monitoring. However, this observation needs to be verified in a larger cohort of patients before any definitive conclusions can be made.
In concordance with earlier studies, our assay to detect TERTp-mutant plasma-tDNA had a low sensitivity(12). Diaz et al. reported that mutant DNA fragments were found in high concentrations in the circulation of most patients with metastatic cancer -e.g. melanoma, breast or colon cancers --and at lower concentrations in patients with localized cancers, as in gliomas or prostate cancer(13,27). Similarly, a recent study showed that levels of CSF-tDNA 
were considered significantly enriched when compared to the corresponding plasma in 12 individuals with primary or metastatic brain tumors(28). In order to improve this shortcoming, new technologies are needed. For instance, an innovative technique employed focused ultrasound to increase the release of brain tumor material into the bloodstream, essentially making blood a viable surrogate for tumor detection (29).
Although we suggest that TERTp mutation detection in the CSF-tDNA has the potential to be developed as a diagnostic instrument in the management of glioblastoma patients, we acknowledge that our approach to collect CSF at the time of surgery was not intended as a preoperative diagnostic tool. From a clinical standpoint, the preoperative detection of TERTp mutation in the CSF-tDNA by lumbar puncture would be more readily accessible than by intraoperative surgery, notwithstanding the consideration of lumbar punctures as an invasive procedure. Consequently, the assessment of genomic alterations at several longitudinal time points as a "liquid biopsy" is a consequential approach to monitor tumor progression and to correlate with radiographic findings. Ultimately, this serial approach may avoid unnecessary surgical procedures and lead to better management of glioblastoma patients. Lastly, a recent study showed a very low congruence for same patient-paired prostate cancer samples between different laboratories(30), raising the question whether the results generated by our assay could be generalized to other laboratories or attained by using different assays. Therefore, to complement our study, confirmatory observational cohorts with more patients and further techniques are certainly needed to determine precise cutoffs of the TERTp mutation VAF that may be used to define patients at high-risk for rapid progression.
In conclusion, our pilot study highlights the value of CSF-tDNA for an accurate and reliable detection of TERTp mutations in glioblastomas. Furthermore, our findings suggest that high 
